A model of the direct and indirect effects of aprotinin administration on the overall costs of coronary revascularization surgery in a university teaching hospital cardiothoracic unit

Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis

“…50%). The results seem at odds with former studies on CABG surgery [21][22][23][24]. However, perioperative cost had been shown not to be significantly different between full-dose or halfdose APR and placebo for primary CABG surgery Fig.…”

“…Several studies have been performed on the economic impact of APR before its withdrawal [20][21][22][23][24]. These studies were based on cost analyses similar to our study since all included at least the drug cost, blood product costs, length of stay and utilization of resources of operating room (including reoperation) and ICU stay.…”

“…These studies were based on cost analyses similar to our study since all included at least the drug cost, blood product costs, length of stay and utilization of resources of operating room (including reoperation) and ICU stay. However, these studies varied on other associated factors like staff grades, staff availability, long-term complications after ICU and surgery cases with a majority of low-risk surgery [20][21][22][23][24]. Nevertheless, they demonstrated that, though APR increased costs due to drug acquisition as well as the cost of administration, its use led to the utilization of fewer resources than with placebo.…”

“…The impact of APR on the economic burden of bleeding and transfusion started to be investigated before the product withdrawal [20][21][22][23]. After years of absence, the expectation regarding the benefits of APR was no longer restricted to its clinical efficacy but also to its cost efficiency.…”

The Pharmacoeconomics of Alternatives to Allogeneic Blood Transfusion

“…35 It was assumed that aprotinin reduces the number of rethoracotomies, decreasing intensive care stay and thus increasing throughput. Savings were projected for aprotinin compared to no pharmacological intervention in direct costs for blood products and through performing fewer rethoracotomies.…”